Literature DB >> 26856453

Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis.

André J Scheen1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 26856453     DOI： 10.1016/j.diabet.2015.12.005

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN： 1262-3636            Impact factor:   6.041


× No keyword cloud information.
  13 in total

Review 1.  Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure.

Authors:  André J Scheen
Journal:  Curr Cardiol Rep       Date:  2019-06-21       Impact factor: 2.931

2.  Diabetes: Time for reconciliation between cardiologists and diabetologists.

Authors:  André J Scheen
Journal:  Nat Rev Cardiol       Date:  2016-07-14       Impact factor: 32.419

3.  Dapagliflozin suppresses glucagon signaling in rodent models of diabetes.

Authors:  May-Yun Wang; Xinxin Yu; Young Lee; Sara Kay McCorkle; Shiuhwei Chen; Jianping Li; Zhao V Wang; Jaime A Davidson; Philipp E Scherer; William L Holland; Roger H Unger; Michael G Roth
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-05       Impact factor: 11.205

Review 4.  Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2017-07       Impact factor: 6.447

Review 5.  Type 2 diabetes in children and adolescents: distinct characteristics and evidence-based management.

Authors:  Kyriaki Karavanaki; Stavroula A Paschou; Nicholas Tentolouris; Foteini Karachaliou; Alexandra Soldatou
Journal:  Endocrine       Date:  2022-08-27       Impact factor: 3.925

Review 6.  Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.

Authors:  Ralph A DeFronzo; Luke Norton; Muhammad Abdul-Ghani
Journal:  Nat Rev Nephrol       Date:  2016-12-12       Impact factor: 28.314

Review 7.  Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Nat Rev Endocrinol       Date:  2020-08-27       Impact factor: 43.330

Review 8.  SGLT2 Inhibitors: Benefit/Risk Balance.

Authors:  André J Scheen
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

Review 9.  Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond.

Authors:  Elif A Oral
Journal:  Drugs Context       Date:  2016-09-02

10.  Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect.

Authors:  Sanjay Kalra; Arpit Jain; Jignesh Ved; A G Unnikrishnan
Journal:  Indian J Endocrinol Metab       Date:  2016 Sep-Oct
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.